- Home
- MNOV vs GNLX Comparison
MNOV vs GNLX Comparison
Compare MNOV & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- GNLX
- Stock Information
- Founded
- MNOV 2000
- GNLX 2001
- Country
- MNOV United States
- GNLX United States
- Employees
- MNOV N/A
- GNLX N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- MNOV Health Care
- GNLX Health Care
- Exchange
- MNOV Nasdaq
- GNLX Nasdaq
- Market Cap
- MNOV 91.7M
- GNLX 85.0M
- IPO Year
- MNOV 2005
- GNLX 2023
- Fundamental
- Price
- MNOV $1.90
- GNLX $4.31
- Analyst Decision
- MNOV Strong Buy
- GNLX Strong Buy
- Analyst Count
- MNOV 1
- GNLX 4
- Target Price
- MNOV $9.00
- GNLX $18.25
- AVG Volume (30 Days)
- MNOV 21.3K
- GNLX 314.9K
- Earning Date
- MNOV 02-18-2025
- GNLX 03-31-2025
- Dividend Yield
- MNOV N/A
- GNLX N/A
- EPS Growth
- MNOV N/A
- GNLX N/A
- EPS
- MNOV N/A
- GNLX N/A
- Revenue
- MNOV N/A
- GNLX $8,000.00
- Revenue This Year
- MNOV N/A
- GNLX N/A
- Revenue Next Year
- MNOV N/A
- GNLX N/A
- P/E Ratio
- MNOV N/A
- GNLX N/A
- Revenue Growth
- MNOV N/A
- GNLX N/A
- 52 Week Low
- MNOV $1.12
- GNLX $1.60
- 52 Week High
- MNOV $2.55
- GNLX $9.82
- Technical
- Relative Strength Index (RSI)
- MNOV 45.15
- GNLX 75.11
- Support Level
- MNOV $1.87
- GNLX $3.20
- Resistance Level
- MNOV $2.06
- GNLX $4.23
- Average True Range (ATR)
- MNOV 0.08
- GNLX 0.56
- MACD
- MNOV 0.00
- GNLX 0.10
- Stochastic Oscillator
- MNOV 47.48
- GNLX 95.73
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.